Back

Development a new enzyme immunoassay for detection anti-EBNA1 antibody to Epstein–Barr virus based on new p72 mosaic protein

Abstract number: p633

Morozova  O., Gladysheva  M., Ulanova  T., Puzyrev  V., Burkov  A., Obriadina  A.

Background: 

The Epstein–Barr virus (EBV) is a human herpes virus 4 (HHV4) that infects and establishes latency in B-lymphocytes. Primary infection leads to a life-long past infection which is normally asymptomatic. EBV expresses a number of genes, however, Epstein–Barr nuclear antigen 1 (EBNA1) p72 is the only viral protein which characterizes EBV past-infection.

Objective: 

The aim of this study was to evaluate diagnostic relevance of new artificial protein composed of 2 antigenic epitopes of the EBV EBNA1 and to develop and evaluate a screening enzyme immunoassay (EIA) for the detection of anti-EBNA1 IgG activity to EBV in serum specimens.

Materials and methods: 

Two potential antigenic epitopes of EBNA1 protein have been predicted by bioinformatics analysis. Mosaic of two antigenic domains from the protein p72 (1–98 aa) and (408–498 aa) of HHV4 was expressed in E. coli as hybrid proteins with Glutathione S-transferase to develop an assay for the detection anti-EBNA1 antibodies. Assay conditions were optimised to reduce the possibility of false positive and false negative results. The new IgG-EIA was evaluated using serum specimens obtained from EBV PCR positive patients (n = 51), HIV-infected individuals (n = 72) and from normal blood donors (BD) (n = 504). All PCR positive specimens were additionally tested for IgG anti-EBNA1 activity by commercially available EIA based on full-length EBV nuclear antigen. The specificity was estimated on the EBV negative samples (n = 23).

Results: 

The EBV past-infection for PCR positive patients was confirmed by the detection of high avidity IgG to EBV Viral Capsid Antigen (VCA). All of the 51 EBV PCR positive patients had IgG antibodies to EBNA1 on the novel EIA. Concordance with commercially available EIA was 98.03%. The frequency of IgG antibodies to EBNA1 in all investigated groups were as follows: 92.21% for health blood donors, 95.39% for HIV-infected individuals and 90.23% for children. Specificity of the assay was around 95.63%.

Conclusion: 

Recombinant protein comprising theoretically predicted antigenic epitopes of EBNA1 protein demonstrated a significant potential as diagnostic reagent. The new EIA is highly specific diagnostic assay for the detection of anti-EBNA1 IgG HHV4 activity in serum specimens and in combination with VCA IgG and IgM may be useful tool for routine diagnosis of acute EBV infections or EBV immune status.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Subject:
Location: Oxford, UK
Presentation type:
Back to top